AI Article Synopsis

  • The study aimed to create a machine learning model to predict thrombolysis resistance in acute ischemic stroke patients receiving rt-PA, addressing poor outcomes in nearly half of such cases.
  • Data from 218 patients showed that the LASSO model was the most effective, achieving a 0.765 AUC, indicating good predictive capability, with key risk factors identified as NIHSS at admission and various blood parameters.
  • The findings emphasize the potential of machine learning in early identification of patients at risk for thrombolysis resistance, which could enhance treatment strategies in clinical settings.

Article Abstract

Background: The objective of this study was to establish a predictive model utilizing machine learning techniques to anticipate the likelihood of thrombolysis resistance (TR) in acute ischaemic stroke (AIS) patients undergoing recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis, given that nearly half of such patients exhibit poor clinical outcomes.

Methods: Retrospective clinical data were collected from AIS patients who underwent intravenous thrombolysis with rt-PA at the First Affiliated Hospital of Bengbu Medical University. Thrombolysis resistance was defined as ([National Institutes of Health Stroke Scale (NIHSS) at admission - 24-hour NIHSS] × 100%/ NIHSS at admission) ≤ 30%. In this study, we developed five machine learning models: logistic regression (LR), extreme gradient boosting (XGBoost), support vector machine (SVM), the least absolute shrinkage and selection operator (LASSO), and random forest (RF). We assessed the model's performance by using receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA), and presented the results through a nomogram.

Results: This study included a total of 218 patients with AIS who were treated with intravenous thrombolysis, 88 patients experienced TR. Among the five machine learning models, the LASSO model performed the best. The area under the curve (AUC) on the testing group was 0.765 (sensitivity: 0.767, specificity: 0.694, accuracy: 0.727). The apparent curve in the calibration curve was similar to the ideal curve, and DCA showed a positive net benefit. Key features associated with TR included NIHSS at admission, blood glucose, white blood cell count, neutrophil count, and blood urea nitrogen.

Conclusion: Machine learning methods with multiple clinical variables can help in early screening of patients at high risk of thrombolysis resistance, particularly in contexts where healthcare resources are limited.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346215PMC
http://dx.doi.org/10.1186/s12883-024-03781-2DOI Listing

Publication Analysis

Top Keywords

thrombolysis resistance
16
machine learning
16
intravenous thrombolysis
12
predictive model
8
ais patients
8
nihss admission
8
learning models
8
curve calibration
8
calibration curve
8
thrombolysis
7

Similar Publications

The body weight-based thrombolytic medication strategy in clinical trials shows critical defects in recanalization rate and post-thrombolysis hemorrhage. Methods for perceiving thrombi heterogeneity of thrombolysis resistance is urgently needed for precise thrombolysis. Here, we revealed the relationship between the thrombin heterogeneity and the thrombolysis resistance in thrombi and created an artificial biomarker-based nano-patrol system with robotic functional logic to perceive and report the thrombolysis resistance of thrombi.

View Article and Find Full Text PDF

Objective: To evaluate the efficacy of butylphthalein injection combined with alteplase thrombolysis in patients with acute cerebral infarction (ACI) and its effects on lipoprotein-associated phospholipase A2 (Lp-PLA2) and CXC chemokine ligand 16 (CXCL16) levels.

Methods: A total of 127 ACI patients admitted to Shandong Provincial Third Hospital between March 2020 and June 2023 were included and divided into a butylphthalein group (n = 67) and a control group (n = 60) based on their treatment regimen. All patients received basic treatment.

View Article and Find Full Text PDF

In 2024, therapeutic and diagnostic advancements are shaping the field of neurology. Three new drugs show promise for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A new classification for Parkinson's disease has been proposed, while a neuroprosthesis is improving gait in advanced stages.

View Article and Find Full Text PDF

This case report presents a 40-year-old transgender female with a history of gender-affirming hormone therapy who experienced recurrent, medication-resistant arterial thrombi leading to bilateral lower extremity amputations. Despite multiple endovascular and surgical interventions, including bypass grafting and catheter-directed thrombolysis, the patient developed recurrent thrombotic events even while on anticoagulation therapy. Hematologic evaluation for coagulopathy was unremarkable.

View Article and Find Full Text PDF

Massive Deep Venous Thrombosis in a Child with Necrotizing Pneumonia Due to Mycoplasma Pneumonia Infection.

Infect Drug Resist

November 2024

Department of Infectious Disease, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, Zhejiang, People's Republic of China.

Article Synopsis
  • * An 8-year-old boy with macrolide-resistant pneumonia developed thrombosis in critical areas, including the pulmonary artery and larger veins, leading to abdominal pain and dangerous thrombi sizes.
  • * After standard anti-infection and anticoagulation treatments failed to alleviate his symptoms and manage the risk of thrombus detachment, the patient underwent specialized procedures that successfully improved his condition and prevented recurrence, underscoring the importance of early thrombosis recognition in pediatric cases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!